Verity Asset Management’s Royalty Pharma RPRX Stock Holding History

Verity Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,431	Closed	-$644K	–	242
2026 Q1	$644K	Sell	13,431 -4,224	-24%	-$185K	0.27%	103
2025 Q4	$682K	Buy	+17,655	New	+$673K	0.29%	94
2022 Q1	$240K	Buy	+6,139	New	+$241K	0.15%	174

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verity Asset Management's RPRX Position: Q2 2026 in Review

Verity Asset Management sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 13,431 shares — an estimated $644K sold.

Verity Asset Management first reported a position in RPRX in Q1 2022 and held it in 3 quarters. The position peaked at $682K in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Verity Asset Management reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
Verity Asset Management sold 13,431 Royalty Pharma shares in Q2 2026, an estimated $644K.
Verity Asset Management first reported a position in Royalty Pharma in Q1 2022 and held it in 3 quarters.
Verity Asset Management's Royalty Pharma position peaked at $682K in Q4 2025.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Verity Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.